{"entity":{"id":"nct06663137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC","aka":[],"tldr":"A phase 2 trial of Docetaxel and Gemcitabine in bladder & urothelial cancer, run by Relmada Therapeutics, Inc., now recruiting.","summary":"A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC is a phase 2 interventional study registered as NCT06663137 by Relmada Therapeutics, Inc., with 70 participants planned, started 2024-08-01 and due to reach its primary completion in 2027-11. Interventions recorded: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06663137","url":"https://clinicaltrials.gov/study/NCT06663137"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["docetaxel","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06663137","phase":"2","setting":"A Single-Center, Open Label, Single Arm Study, to Evaluate the Safety and Efficacy of NDV-01 KIT in Participants With Non Muscle Invasive Bladder Cancer (NMIBC)","sponsor":"Relmada Therapeutics, Inc.","enrolled":70,"outcomes":[]},"route":"/trials/nct06663137/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}]}}